Q1 2026 Alkem Laboratories Ltd Earnings Call Transcript
Key Points
- Alkem Laboratories Ltd (BOM:539523) reported a strong start to FY26 with a total revenue from operations of INR33,711 million, marking a year-over-year growth of 11.2%.
- The company's EBITDA grew by 21.4% year-over-year to INR7,391 million, resulting in an improved EBITDA margin of 21.9%.
- Domestic revenue contributed 68.3% to total sales in Q1 FY26, up from 67.6% in Q1 FY25, indicating strong performance in the Indian market.
- The company outperformed the Indian Pharmaceutical Market (IPM) across seven key therapies, with significant growth in areas such as vitamins and minerals, pain, and anti-diabetics.
- Alkem Laboratories Ltd (BOM:539523) commenced revenue generation from its Alkem Medtech initiative, showing potential for future growth in this new business segment.
- Despite the strong performance, the company is cautious about revising its FY26 guidance, citing it as too early to make changes based on just one quarter's results.
- R&D expenses were lower than expected at 3.5% of total revenue, but the company anticipates higher R&D spending in subsequent quarters, which could impact margins.
- The US business experienced a 3% to 4% price erosion year-over-year, which negatively impacted gross margins despite overall revenue growth.
- The Medtech business, while promising, is currently contributing minimally to overall revenue and is expected to incur losses of INR40 crores to INR50 crores in FY26 and FY27.
- Operational expenses for new initiatives, such as the US CDMO facility and Medtech business, are expected to increase, potentially affecting overall profitability in the short term.
(Operator Instructions) Ladies and gentlemen, good day, and welcome to the Alkem Lab Q1 FY26 earnings conference call hosted by Motilal Oswal. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Tushar Manudhane from Motilal Oswal. Thank you, and over to you, sir.
Thanks, Shakar. Good evening, and warm welcome to First Quarter FY26 earnings call of Alkem Laboratories. From the management side, we have Mr. Vikas Gupta, CEO; Mr. Nitin Agrawal, CFO; and Mr. Purvi Shah, Head of Investor Relations.
Over to you, Purvi.
Thank you, Tushar. Good evening, everyone. We appreciate you joining us for our Q1 FY26 results call. Earlier today, we've released our financial results, press release and results presentation, all of which are available on our website and have also been filed with the stock exchanges. We hope you've had a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
